Rugo HS - Search Results

1

Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.

Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS; I-SPY 1 TRIAL Investigators; Esserman L, Park JW, van 't Veer LJ. Magbanua MJ, et al. Among authors: rugo hs. Breast Cancer Res. 2015 May 29;17(1):73. doi: 10.1186/s13058-015-0582-3. Breast Cancer Res. 2015. PMID: 26021444 Free PMC article.

2

High-dose chemotherapy (CTM) for breast cancer.

Damon LE, Wolf JL, Rugo HS, Gold E, Zander AR, Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, Linker CA. Damon LE, et al. Among authors: rugo hs. Bone Marrow Transplant. 2000 Aug;26(3):257-68. doi: 10.1038/sj.bmt.1702481. Bone Marrow Transplant. 2000. PMID: 10967563 Clinical Trial.

3

Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation.

Lang JE, Esserman LJ, Ewing CA, Rugo HS, Lane KT, Leong SP, Hwang ES. Lang JE, et al. Among authors: rugo hs. J Am Coll Surg. 2004 Dec;199(6):856-62. doi: 10.1016/j.jamcollsurg.2004.08.023. J Am Coll Surg. 2004. PMID: 15555967

4

MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. Partridge SC, et al. Among authors: rugo hs. AJR Am J Roentgenol. 2005 Jun;184(6):1774-81. doi: 10.2214/ajr.184.6.01841774. AJR Am J Roentgenol. 2005. PMID: 15908529

5

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Rugo HS, et al. J Clin Oncol. 2005 Aug 20;23(24):5474-83. doi: 10.1200/JCO.2005.04.192. Epub 2005 Jul 18. J Clin Oncol. 2005. PMID: 16027439 Clinical Trial.

6

The importance of distant metastases in hormone-sensitive breast cancer.

Rugo HS. Rugo HS. Breast. 2008 Jan;17 Suppl 1:S3-8. doi: 10.1016/S0960-9776(08)70002-X. Breast. 2008. PMID: 18279764 Review.

7

Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates.

Belkora J, Rugo HS, Moore DH, Hutton D, Esserman L. Belkora J, et al. Among authors: rugo hs. Lancet Oncol. 2008 Jul;9(7):602-3. doi: 10.1016/S1470-2045(08)70158-X. Lancet Oncol. 2008. PMID: 18598923 No abstract available.

8

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.

Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. Dickler MN, et al. Among authors: rugo hs. Clin Cancer Res. 2008 Dec 1;14(23):7878-83. doi: 10.1158/1078-0432.CCR-08-0141. Clin Cancer Res. 2008. PMID: 19047117 Free PMC article. Clinical Trial.

9

Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.

Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman LJ. Belkora JK, et al. Among authors: rugo hs. BMC Cancer. 2009 Apr 28;9:127. doi: 10.1186/1471-2407-9-127. BMC Cancer. 2009. PMID: 19400938 Free PMC article.

10

Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.

Greenberg S, Rugo HS. Greenberg S, et al. Among authors: rugo hs. Clin Breast Cancer. 2010 Sep;10 Suppl 2:S20-9. doi: 10.3816/CBC.2010.s.009. Clin Breast Cancer. 2010. PMID: 20805062 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

500 results

Search Page